A group of neuroscientists has retracted a paper published earlier this last year in Diabetes after realizing that a figure that took up a whole page of the paper may not have been quite right.
Here’s the notice for “Blockade of receptor for advanced glycation end products in a model of type 1 diabetic leukoencephalopathy”: Continue reading Authors retract Diabetes paper after submitting it “without knowledge of inherent errors”
A coding switcharoo caused a paper Society & Natural Resources to be retracted. But the authors say that not all is lost, since correcting the data gave them a better understanding of how the the U.S. Environmental Protection Agency fines companies that pollute in poor and minority neighborhoods.
The retraction notice reads: Continue reading Paper on “evidence for environmental racism” in EPA polluter fines retracted for coding error
Last month, we brought you news that Pfizer had retracted a paper in the Journal of Clinical Oncology
purporting to show a benefit of their experimental drug for lung cancer figitumumab after discovering that its clinical lead on the project had done analyses improperly.
There’s been another retraction, of a related paper, in the British Journal of Cancer, “Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab.” Here’s the notice: Continue reading Another retraction for Pfizer’s experimental cancer treatment figitumumab
The Journal of Neuro-Oncology wants you to ignore the following paper: “A single chain (scFv425):sTRAIL fusion protein with specificity for the EGF receptor is effective in vitro but not in an in vivo brain tumor animal model.”
The 2007 article, from a group in The Netherlands, suffered from two fatal problems. According to the retraction notice: Continue reading “This publication should be ignored”: Authorship issues, flawed data fell neuro-oncology paper
In August of last year, Mladen Pavičić, chair of physics at the University of Zagreb’s Faculty of Civil Engineering, published a paper in Physical Review Letters on quantum teleportation, “Near-Deterministic Discrimination of All Bell States with Linear Optics.”
Just six days later, after hearing from a physicist in China, Pavičić — who is also affiliated with Harvard’s physics department — submitted a correction, which ran on the journal’s site in November. The correction begins: Continue reading Poignancy in physics: Retraction for “fatal error” that couldn’t be patched
The list of Ulrich Lichtenthaler retractions has grown to eight.
Here’s the new notice, for “Externally commercializing technology assets: An examination of different process stages,” from the Journal of Business Venturing: Continue reading What’s new is not new again: Ulrich Lichtenthaler retracts eighth paper
The Journal of Vinyl and Additive Technology (JVAT) — the official journal of the Society of Plastics Engineers — is retracting a 2012 paper from a group of Chinese researchers who evidently realized at some point that they didn’t know quite what they were doing.
As the notice explains: Continue reading Retraction is final destination for epoxy paper marred by “pervasive misattribution of data”
A group of Dutch researchers has retracted a paper they published in March after apparently learning that they’d bungled their statistical analysis in the study.
The article, “Effects of a pre-visit educational website on information recall and needs fulfilment in breast cancer genetic counselling, a randomized controlled trial,” was published in Breast Cancer Research by Akke Albada of the Netherlands Institute for Health Services Research and colleagues.
But according to the notice, Utrecht, we have a problem: Continue reading Intent was there, but not the intention-to-treat analysis: Breast cancer study retracted
Pfizer has retracted a 2009 Journal of Clinical Oncology study purporting to show a benefit of their experimental drug for lung cancer figitumumab after discovering that its clinical lead on the project had done analyses improperly.
Here’s the text of the notice: Continue reading Pfizer retracts study of experimental cancer treatment figitumumab for incorrect analyses
The authors of a study on cancer incidence and survival in the Dutch migrant community have retracted it after realizing they’d made some errors that significantly affected the results.
But in what seems like an appropriate reward for coming forward, the newly analyzed data, with additional information, will be part of a forthcoming paper in another journal by the same authors.
The original retrospective study came out in May 2011 in the European Journal of Cancer Prevention and found that risk and survival of breast and stomach cancers differed depending on the person’s mother country. The problem was that the study jumbled up many of the participants’ homelands during the analysis.
The authors issued the following retraction: Continue reading Jumbled analysis leads to retraction of cancer study — but also another paper